The primary objective of the SLEEPLAY study is to assess the feasibility of a research protocol investigating the impact of video games on sleep in adults. More specifically, this study aims to identify potential barriers, facilitators of participation, and participant adherence to various measurement tools (such as actigraphy and melatonin assays) to validate the protocol for a larger future study. Additionally, it seeks to optimize the recruitment of regular adult gamers and determine the conditions that will enable better collection of objective sleep data. The relevance of this feasibility study lies in its ability to test and refine the methodology, thereby facilitating future research while minimizing costs and implementation time.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
40
Participants will engage in a structured protocol to assess sleep patterns and potential disturbances related to video game usage. This protocol includes: * Completion of diaries: Participants will maintain a sleep diary, video game usage diary, and screen time diary for 14 days to record their activities and sleep quality. * Clinical assessments: At Visit 2, participants will complete questionnaires related to sleep quality and disturbances, administered by a sleep specialist neurologist. * Actigraphy monitoring: Participants will wear an actimeter during the 14-day recording period to objectively measure sleep activity. * Biological sampling: After the 14 days, participants will provide urinary samples for analysis of 6-sulfatoxymelatonin to evaluate melatonin levels.
CHU de Besançon
Besançon, France
RECRUITINGRecruitment Capacity
Number of participants successfully included in the study per month within each group (Regular Gamers and Non-Gamers).
Time frame: Month 20 of the study
Attrition rate
Percentage of participants who drop out of the study.
Time frame: Month 21 at the end of the study
Data Completeness
Mean number of days with valid data for: sleep diary, video game and screen-use diary, actigraphy (≥90% wear time), urinary samples for 6-sulfatoxymelatonin
Time frame: Month 21 at the end of the study
Acceptability
Proportion of subjects who accepted to participate in the study compared to the number of eligible patients contacted.
Time frame: Month 20 of the study
Average Sleep Onset Latency
Duration between going to bed and falling asleep, expressed in minutes (average calculated over 14 days)
Time frame: Month 1
Total Sleep Time (minutes) measured by wrist actigraphy.
Total nightly sleep duration estimated objectively using actigraphy.
Time frame: Up to Day 25 post-inclusion
Sleep Onset Latency (minutes) from daily sleep diary.
Time between lying down and perceived sleep onset, self-reported each morning.
Time frame: Up to Day 25 post-inclusion
Sleep Efficiency (Actigraphy)
Sleep Efficiency (%) measured by actigraphy.
Time frame: Up to Day 25 post-inclusion
Circadian Phase Marker - 6-SMT Acrophase
6-sulfatoxymelatonin acrophase (clock time, hh:mm).
Time frame: Up to Day 25 post-inclusion
Pittsburgh Sleep Quality Index (PSQI)
Global sleep quality score from the Pittsburgh Sleep Quality Index; higher scores indicate poorer sleep quality.
Time frame: Up to Day 25 post-inclusion
Insomnia Severity Index (ISI)
Insomnia severity score; higher scores indicate more severe insomnia symptoms.
Time frame: Up to Day 25 post-inclusion
Morningness-Eveningness Questionnaire (MEQ)
MEQ total score (16-86). Chronotype score; higher scores indicate stronger morningness preference.
Time frame: Up to Day 25 post-inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.